# ROSALINE (NCT04551495)

> Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04551495
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Jules Bordet Institute
- Conditions: Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer
- Interventions: Entrectinib; Letrozole; Goserelin
- Enrollment: 65
- Primary outcome: Evaluation of the efficacy of endocrine therapy + entrectinib in women with ER+/HER2- early breast cancer of the lobular subtype:Residual Cancer Burden (RCB)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rosaline-nct04551495

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04551495", "email": "<work email>"}; the inbox owner confirms by the emailed link.